Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
119M
-
Number of holders
-
100
-
Total 13F shares, excl. options
-
45.7M
-
Shares change
-
+197K
-
Total reported value, excl. options
-
$1.09B
-
Value change
-
+$4.2M
-
Put/Call ratio
-
0.45
-
Number of buys
-
37
-
Number of sells
-
-44
-
Price
-
$23.89
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) as of Q3 2021
118 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2021.
Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) has 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.7M shares
of 119M outstanding shares and own 38.3% of the company stock.
Largest 10 shareholders include FRAZIER MANAGEMENT LLC (8.43M shares), FMR LLC (7.54M shares), ORBIMED ADVISORS LLC (6.07M shares), BlackRock Inc. (4.2M shares), Bain Capital Life Sciences Investors, LLC (3.98M shares), Point72 Asset Management, L.P. (1.99M shares), Polar Capital Holdings Plc (1.55M shares), VANGUARD GROUP INC (1.49M shares), STATE STREET CORP (1.04M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (814K shares).
This table shows the top 100 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.